Patience3to6Lumen
OP
:
There is a likelihood that TNXP will get final FDA approval for their drug, potentially by the second half of 2025, but there is also a 50% chance the company might undergo another dilution. If that happens, the extent of dilution is uncertain. Additionally, the company must stay in compliance with NASDAQ listing rules by February 2025. Given these risks, it’s important to approach investing cautiously, even for the long term. It would be safer to consider entering once there is more visibility and certainty.
101674396 : May be chance to reverse split !!!
103217649 : Good to hold long term for this price…
Patience3to6Lumen OP : There is a likelihood that TNXP will get final FDA approval for their drug, potentially by the second half of 2025, but there is also a 50% chance the company might undergo another dilution. If that happens, the extent of dilution is uncertain. Additionally, the company must stay in compliance with NASDAQ listing rules by February 2025. Given these risks, it’s important to approach investing cautiously, even for the long term. It would be safer to consider entering once there is more visibility and certainty.